Enovis (NYSE:ENOV) Insider Oliver Engert Buys 2,660 Shares

Enovis Corporation (NYSE:ENOV) insider Oliver Engert acquired 2,660 shares of Enovis stock in a transaction that occurred on Friday, September 4th. The shares were purchased at an average cost of $18.80 per share, for a total transaction of $50,008.00. Following the purchase, the insider directly owned 63,898 shares in the company, valued at $1,201,282.40. The trade was a 4.34% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Oliver Engert also recently made the following trade(s):

• On Wednesday, September 2nd, Oliver Engert bought 2,458 shares of Enovis stock. The stock was purchased at an average cost of $20.32 per share, with a total value of $49,946.56.
• On Thursday, September 3rd, Oliver Engert bought 5,140 shares of Enovis stock. The stock was purchased at an average price of $19.46 per share, for a total transaction of $100,024.40.
• On Monday, June 15th, Oliver Engert acquired 1,000 shares of Enovis stock. The stock was purchased at an average price of $20.92 per share, with a total value of $20,920.00.
• On Thursday, June 11th, Oliver Engert bought 1,200 shares of Enovis stock. The shares were acquired at an average price of $21.62 per share, for a total transaction of $25,944.00.
• On Wednesday, June 10th, Oliver Engert purchased 1,000 shares of Enovis stock. The stock was acquired at an average price of $23.00 per share, with a total value of $23,000.00.

Enovis Stock Up 7.5%

Shares of NYSE ENOV traded up $1.39 during mid-day trading on Tuesday, reaching $19.95. 3,742,680 shares of the company’s stock were exchanged, compared to its average volume of 1,103,625. The firm has a market capitalization of $1.15 billion, a price-to-earnings ratio of -1.04 and a beta of 1.31. The company has a current ratio of 1.98, a quick ratio of 1.00 and a debt-to-equity ratio of 0.84. The business has a fifty day simple moving average of $25.42 and a 200 day simple moving average of $24.18. Enovis Corporation has a twelve month low of $18.52 and a twelve month high of $34.28.

Enovis (NYSE:ENOV) last issued its quarterly earnings data on Thursday, August 6th. The company reported $0.90 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.85 by $0.05. Enovis had a positive return on equity of 12.03% and a negative net margin of 47.96%.The business had revenue of $582.78 million during the quarter, compared to analyst estimates of $581.84 million. During the same period in the previous year, the firm earned $0.79 EPS. Enovis’s quarterly revenue was up 3.2% compared to the same quarter last year. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. As a group, equities analysts expect that Enovis Corporation will post 3.15 EPS for the current fiscal year.

Institutional Trading of Enovis

Hedge funds and other institutional investors have recently modified their holdings of the stock. Arax Advisory Partners bought a new position in Enovis in the fourth quarter valued at approximately $29,000. EverSource Wealth Advisors LLC boosted its holdings in shares of Enovis by 125.4% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 1,271 shares of the company’s stock valued at $40,000 after buying an additional 707 shares during the last quarter. Allworth Financial LP bought a new position in shares of Enovis in the second quarter valued at $36,000. Danske Bank A S bought a new position in shares of Enovis in the third quarter valued at $64,000. Finally, Public Employees Retirement System of Ohio acquired a new position in Enovis during the second quarter worth $48,000. Institutional investors and hedge funds own 98.45% of the company’s stock.

Analyst Upgrades and Downgrades

ENOV has been the topic of a number of research reports. BTIG Research cut their price target on Enovis from $40.00 to $36.00 and set a “buy” rating on the stock in a report on Tuesday, September 1st. BMO Capital Markets set a $27.00 price objective on Enovis in a report on Tuesday, September 1st. Canaccord Genuity Group dropped their target price on Enovis from $50.00 to $45.00 and set a “buy” rating on the stock in a research report on Monday, August 17th. Wells Fargo & Company cut their target price on Enovis from $39.00 to $33.00 and set an “overweight” rating on the stock in a research note on Wednesday, September 2nd. Finally, UBS Group reaffirmed a “buy” rating and set a $51.00 price target (up from $50.00) on shares of Enovis in a research report on Tuesday, July 28th. Ten analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Enovis currently has an average rating of “Moderate Buy” and a consensus price target of $40.38.

About Enovis

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.